Experimental

Solid-phase synthesis of substrates 1-11 S4
Scheme S1. Solid-phase synthesis of substrates 1-3 S5
Supporting Figures
Figure S1
. Preliminary screen of time-dependent activation of substrates 1-11 (2.5, 5 and 10 µM, n = 3) with caspase-3 (15 nM). 
Experimental
Solid-phase synthesis of 1-11
The fluorogenic substrates 1-11 were synthesised (Scheme S1 and S2) on aminomethyl polystyrene resin (1 % DVB, 100-200 mesh, loading 1.
-dimethoxybenzyl}-phenoxyacetic acid) was coupled to the resin, using the general coupling procedure below. The bifunctional spacer Fmoc-Lys(Dde)-OH (synthesised as reported by Portal 1 ) was then coupled, followed by Fmoc deprotection and coupling of the relevant amino acid sequence (including εAhx-spacers where present). Once the sequences were complete, the Dde protecting group was removed with NH 2 OH·HCl/imidazole in NMP-DCM (see below), 2 and methyl red coupled to the lysine side chain. The N-terminus Fmoc group was then deprotected and 5(6)-carboxyfluorescein coupled. Ninhydrin and acetaldehyde/chloranil tests were used to confirm the presence of amines after each deprotection and coupling step. After cleavage from the resin, the compounds were purified by preparative HPLC, and analysed by MALDI-ToF MS and HPLC. 
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Scheme S1. Solid-phase synthesis of substrates 1-3.
Scheme S2. Solid-phase synthesis of substrates 4-11. 
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Coupling procedure. The appropriate Fmoc-protected amino acid (4 eq, 0.1 M) and Oxyma (4 eq) in DMF was stirred for 10 min. DIC (4 eq) was added and the mixture stirred for a further 5 min. The coupling solution was added to the corresponding resin (1 eq, ~ 250 mg resin), preswollen in DCM, and shaken for 1 hr. After filtration, the resin was washed with DMF (3 × 10 mL), DCM (3 × 10 mL), and MeOH (3 × 10 mL).
Fmoc deprotection. The resin was preswollen in DCM, and treated with 20 % piperidine in DMF (v/v) (3 mL, 2 × 5 min). The resin was isolated by filtration, and washed with DMF (3 × 10 mL), DCM (3 × 10 mL), and MeOH (3 × 10 mL).
Dde deprotection. NH 2 OH·HCl (1.25 g, 1.80 mmol) and imidazole (0.92 g, 1.35 mmol) were suspended in 5 mL of NMP and the mixture was sonicated until complete dissolution. Before the reaction, 5 volumes of the deprotection solution were diluted with 1 volume of DCM. The solution was added to the corresponding resin (100-125 mg, 20 mg/mL), stirred for 2 h, the deprotected resin was isolated by filtration, and washed with DMF (3 × 10 mL), DCM (3 × 10 mL), and MeOH (3 × 10 mL).
Cleavage from the resin. Prior to cleavage, the resin was additionally washed with 20% piperidine in DMF.
The resin (100-125 mg), preswollen in DCM, was treated with 2-3 mL of TFA-TIS-H 2 O (95:2.5:2.5) for 3 h.
The cleavage solution was isolated from the resin by filtration, and the compounds precipitated by addition of cold Et 2 O and isolated as dark red solids by centrifugation.
Purification and characterisation of 1-11
Preparative HPLC was performed using Agilent Technologies 1100 instrument with UV detection (collection Sinapic acid was used as a matrix. 
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3.
Enzymatic assays 
E. coli-derived
Kinetic assays with Caspase-3/7
Each substrate was dissolved in DMSO to give 10-100 mM stock solutions (stored at −20 °C). The rate (µM/min) was calibrated using a 5(6)-carboxyfluorescein conversion factor (0.0045 µM/RFU) and the data plotted against time (min). For initial cleavage rate (0-5 min), plots were fitted using linear regression analysis and the Michaelis-Menten data generated using GraphPad Prism 5. For AFC and MCA (λ Ex/Em 355/460 nm) 0.4-25 µM substrate concentrations were used (conversion factor 0.0003 µM/RFU for AFC).
The fluorescence from the controls (no enzyme) was removed from the total fluorescence increase of the samples to determine background corrected RFU.
